PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031 Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE ersons are required to respond to a collection of information unless it contains a valid OMB control number. Under the Paperwork Reduction Act of 1995. Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet of

BACK	Complete if Known	
Application Number	10/774,697	
Filing Date	February 10, 2004	
First Named Inventor	Richard A. COUCH et al.	
Group Art Unit	1015-1614	
Examiner Name	Unassigned LESUE ROYAS	
Attorney Docket Number	PHARMA-0148	

	U.S. PATENT DOCUMENTS							
Examiner Initials *	Cite No.1	U.S. Patent Document Kind Code ² Number (if known)		Date of Publication of Cited Document MM-DD-YYYY				
LAR	A1	2002/0058061 A1		Kamai K. MIDHA et al.	05/16/2002			
		*						
				<u></u>				
				 				
	 		+					
		,,	 					
_			1					
			1					

	FOREIGN PATENT DOCUMENTS							
			Foreign Patent Docum	nent	·	Date of Publication of	Pages, Columns, Lines, Where Relevant	
Examiner Initiats*	Cite No.1	Office ³	Number ⁴	Kind Code ⁵ (if known)	Name of Patentee or Applicant of Cited Document	Cited Document MM-DD-YYYY	Passages or Relevant Figures Appear	T ⁶
LAR	B1	wo	2002/039998 A3		PCT	05/23/2002		
LAR	B2	wo	00/23055		PCT	04/27/2000		
LAR	В3	wo	03/092661 A1		PCT	11/13/2003		
LAR	B4	wo	03/072105 A1		PCT	09/04/2003		
	لم		In N N V	/				

Examiner Signature Date Considered 25 May 2005

EXAMINER: Initial if eference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered include copy of this form with n xt dommunication to applicant.

1 Unique citation designation number. 2 See attached sinds of U.S. Patent Documents. 3 Enter Office that Issued the document, by the two-letter code (WIPO Standard ST.3). For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. 6 Applicant is to place a check mark here if English language Translation is attached. Number refers to English language corresponding family member.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner of Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

a plus sign (+) inside this bo

PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031 (U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no easy are required to respond to a collection of information unless it contains a valid CMB control number

Substitute for form 1449A/PTO

Examiner

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

	Complete if Known	
Application Number	10/774,697	
Filing Date	February 10, 2004	_
First Named Inventor	Richard A. COUCH et al.	
Group Art Unit	-1615-1614	_
Examiner Name	-Unassigned LESLIE ROYDS	
Attorney Docket Number	PHARMA-0148	7

		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials *	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	۲2
LAR	C1	L. EUGENE ARNOLD et al., Levoamphetamine and Dextroamphetamine: Comparative Efficacy in the Hyperkinetic Syndrome, Assessment by Target Symptoms, Arch Gen Psychiat, Vol. 27, December 1972, pages 816-822	
LAR	C2	L. EUGENE ARNOLD et al., Levoamphetamine and Dextroamphetamine: Differential Effect on Aggression and Hyperkinesis in Children and Dogs, Am J Psychiatry 130:2, February 1973, pages 165-170	
LAR	СЗ	SIMON J. TULLOCH, et al., SLI381 (Adderall XR), a Two-Component, Extended-Release Formulation of Mixed Amphetamine Salts: Bioavailability of Three Test Formulations and Comparison of Fasted, Fed, and Sprinkled Administration, Pharmacotheraphy, Vol. 22, Number 11, 2002, pages 1405-1415	
LAR	C4	KENNERLY S. PATRICK et al., Pharmacology of Methylphenidate, Amphetamine Enantiomers and Pemoline in Attention-Deficit Hyperactivity Disorder, Human Psychopharmacology, Vol. 12, pages 527-546 (1997)	
			
		·	
			 -

25 May 2005 Signature Considered EXAMINER: Initial Meterolog considered, whether or tot citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Date

¹ Unique citation designation number. 2 Applicant Is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner of Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Approved for use through 10/31/2002. OMB 0651-0031° S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE spond to a collection of information unless it contains a valid OMB control number. Under the Paperwork Reduction Act of 199

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet of

MARI	Complete if Known	
Application Number	10/774,697	
Filing Date	February 10, 2004	
First Named Inventor	Richard A. COUCH et al.	
Group Art Unit	1813 614	
Examiner Name	-Unknown LESLIEROYDS	
Attorney Docket Number	PHARMA-0148	

	U.S. PATENT DOCUMENTS							
		U.S. Patent Documer			Date of Publication of Cited Document			
Examiner Initials *	Cite No.1	Number	Kind Code ² (if known)	Name of Patentee or Applicant of Cited Document	MM-DD-YYYY			
LAR	1	6,605,300	B1	Beth A. Burnside et al.	08-12-2003			
	<u> </u>							
			-		 			
					 			
			-					
		_	1					
		·						
		· · · · · · · · · · · · · · · · · · ·						

	FOREIGN PATENT DOCUMENTS							
	Foreign Patent Document			Date of Publication of	Pages, Columns, Lines, Where Relevant			
Examiner Initials* Cite No.*		Office ³	Number ⁴	Kind Code ⁵ (if known)	Name of Patentee or Applicant of Cited Document		Passages or Relevant Figures Appear	T⁰
	L							
				·				
						•		
					·			
	<u> </u>							
			$\langle \langle N \rangle \rangle$					
Examine Signature	, (W Search		Date Considered	25 May 20	os	$\overline{}$

EXAMINER: Initial of reference considered, whither or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner of Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Unique citation designation number. 2 See attached Kinds of U.S. Patent Documents. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). For Japanese patent occurrents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. Skind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. Applicant is to place a check mark here if English language Translation is attached. Number refers to English language corresponding family member.

Please type a plus sign (+) inside this box

PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

Approved for use through 10/31/2002. OMB 0651-0031

Under the Paperwork Reduction Act of 1995, no parsers are require to respond to a collection of information unless it contains a valid OMB control number of form 1449A/PTO

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet of

	Complete if Known	
Application Number	10/774,697	
Filing Date	February 10, 2004	
First Named Inventor	Richard A. COUCH et al.	
Group Art Unit	1615 1614	
Examiner Name	Unknown LESLIE ROYDS	
Attorney Docket Number	PHARMA-0148	

	real production of the contract of the contrac	NON PATENT LITERATURE DOCUMENTS	
Examiner Initials *	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the Item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
LAR	2	Psychopharmacology 50, 171-175 (1976), Sleep: Effects of <i>d</i> - and <i>l</i> -Amphetamine in Man and in Rat, Emest Hartmann et al.	
LAR	3	The Journal of Pharmacology and Experimental Therapeutics, Vol. 194, No. 1, Amphetamine: Evaluation of d- And I-Isomers As Releasing Agents And Uptake Inhibitors For 3H-Dopamine and 3H-Norepinephrine In Slices Of Rat Neostraitum And Cerebral Cortex, Richard E. Heikkila et al., pages 47-56.	
LAR	4	Biochemical Pharmacology, Vol. 25, pp. 447-451, Effects Of The d- And I-Isomers Of Amphetamine On Uptake, Release And Catabolism Of Norepinephrine, Dopamine And 5-Hydroxytryptamine In Several Regions Of Rat Brain, John C. Holmes et al.	
		·	
			-
	, ,		
		() , (X (\)	

Examiner Date 25 May 2005 Signature Considered

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner of Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.